期刊
NANOSCALE
卷 13, 期 48, 页码 20401-20411出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1nr03180e
关键词
-
类别
资金
- iCASE award from Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M017397/1]
- Waters Corporation
- John and Lucille van Geest Foundation
- National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit
This study utilized nano molecularly imprinted polymers (nanoMIPs) to capture the critical oncogene KRAS, allowing for the determination of mutations and discovery of epitopes using LC-MS technology. The approach demonstrated the potential for precise genotyping of cancer cell lines and patients through the use of nanoMIPs, indicating a promising translation from research to clinical utility.
Cancer is a disease of cellular evolution where single base changes in the genetic code can have significant impact on the translation of proteins and their activity. Thus, in cancer research there is significant interest in methods that can determine mutations and identify the significant binding sites (epitopes) of antibodies to proteins in order to develop novel therapies. Nano molecularly imprinted polymers (nanoMIPs) provide an alternative to antibodies as reagents capable of specifically capturing target molecules depending on their structure. In this study, we used nanoMIPs to capture KRAS, a critical oncogene, to identify mutations which when present are indicative of oncological progress. Herein, coupling nanoMIPs (capture) and liquid chromatography-mass spectrometry (detection), LC-MS has allowed us to investigate mutational assignment and epitope discovery. Specifically, we have shown epitope discovery by generating nanoMIPs to a recombinant KRAS protein and identifying three regions of the protein which have been previously assigned as epitopes using much more time-consuming protocols. The mutation status of the released tryptic peptide was identified by LC-MS following capture of the conserved region of KRAS using nanoMIPS, which were tryptically digested, thus releasing the sequence of a non-conserved (mutated) region. This approach was tested in cell lines where we showed the effective genotyping of a KRAS cell line and in the plasma of cancer patients, thus demonstrating its ability to diagnose precisely the mutational status of a patient. This work provides a clear line-of-sight for the use of nanoMIPs to its translation from research into diagnostic and clinical utility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据